Cerebral blood flow (CBF) was estimated from measurements of internal carotid blood flow and sagittal sinus blood flow in mechanically ven tilated rabbits under 70% NzO-30% O2, Intravenously administered physo stigmine, a cholinesterase inhibitor, increased CBF under normocapnia and enhanced the cerebral vasodilatation of hypercapnia, but did not alter the cere bral metabolic rate of oxygen (CMR02), The cerebrovascular effects of physo stigmine were antagonized by atropine but not by dihydro-beta-erythroidine, a ,nicotinic blocker. Neostigmine, a quaternary cholinesterase inhibitor that does not cross the blood-brain barrier, showed no cerebrovascular effects, It is concluded that the cholinergic cerebral vasodilatation does not depend on cerebral metabolic activation, and that the cholinergic receptors involved are muscarinic and located beyond the blood-brain barrier. Key Words: Atropine Cerebral blood flow-Cerebral O2 uptake-Physostigmine-Rabbit.
A physiological role of cholinergic mechanisms in regulation of cerebral blood flow (CBF) is suggested by the cerebrovascular effect of the cholinesterase inhibitor physostigmine, which enhances the cere bral vasodilatation associated with cortical arousal or hypercapnia Scremin et al., 1978) . Moreover, atropine blocks the vasodilatation occurring in those cir cumstances (Scremin et al., , 1978 and during hypotension (Mchedlishvili and Nikolaishvili, 1970) . In addition, cholinergic agonists are known both to increase CBF and to dilate pial vessels (Kuschinsky et al., 1974) when applied locally to the cerebral cortex.
A central question in the interpretation of these effects of cholinergic drugs, however, is whether the vasodilatation induced by these agents is associated with an increase in the metabolic rate of the brain. If this is the case, the cerebrovascular effects might be secondary to the action of vasodilator metabolites. A possible lack of involvement of metabolic activa tion in the cholinergic vasodilatation was suggested by our earlier observation that muscarinic agonists were still able to elicit an increase in cortical blood flow after neuronal electrical activity was abolished pharmacologically .
To gain insight into this problem, cerebral O2 up take was measured in the present experiments as an index of aerobic metabolism of the brain during the vasodilatation induced by physostigmine. In addi tion, the nature of the cholinergic receptors in volved was studied by the use of the nicotinic and muscarinic blockers dihydro-beta-erythroidine and atropine, respectively, which are known to act on the central nervous system when injected intrave nously (Eccles et al., 1954; Curtis et al., 1957; Weiner, 1980) . The relation of the receptors to the blood-brain barrier was also explored by comparing the effects on CBF of physostigmine, which crosses the blood-brain barrier, with those of the quaternary cholinesterase inhibitor neostigmine, which does not (Koelle and Steiner, 1956) . Some preliminary results of the study here described have appeared in abstract form (Scremin et aI., 1979) .
METHODS
Sixteen New Zealand male rabbits weighing 2.5-3 kg were used. Anesthesia was induced with 4% halothane in 70% N20-30% O2, and then maintained with 2% halothane in 70% N20-30% O2 until completion of all surgical preparative proce dures. The trachea was cannulated, and the animal was paralyzed with pancuronium bromide (Pavu lon®, Organon, 0.2 mg kg-1 h-1, i.v.) and mechani cally ventilated to achieve an end-tidal CO2 (ETC02) of 4% (normocapnia), as measured by a Beckman LB2 gas analyzer. (In six control experiments, the ratio of P aC02, measured on a Radiometer blood gas analyzer, to ETC02 averaged 7.03 ± 0.16 (SE) at the beginning of the experiment and 7.36 ± 0.26 2 h later; the difference was statistically insignificant.)
A femoral artery, a femoral vein, and an auricular vein were cannulated for recording of arterial blood pressure via a Statham transducer, for withdrawal of arterial blood samples, and for infusion of drugs. Esophageal temperature was monitored continu ously and maintained at 38°C by radiant heating of the animal After completion of the surgical preparations de scribed below, halothane was discontinued and the animals were maintained on 70% N20-30% O2, One hour was allowed between discontinuation of halothane and the first determinations of dorsal sagittal sinus blood flow (SSBF), cerebral metabolic rate of oxygen (CMR02), or of internal carotid blood flow (ICBF). SSBF, CMR02, and ICBF are expressed as percentages of their values at ETC02 of 4% immediately prior to the experimental ma nipulations.
Recording of SSBF and CMR02
The dorsal sagittal sinus was exposed by drilling the parietal bone; heparin was given i.v. (1,000 USP units/h); and the vessel was cannulated with PE 90 polyethylene tubing, which completely occluded it. The sagittal sinus drains solely the dorsolateral parts of the fronto-parietal cortices in the rabbit (Scremin et aI., 1982) . The blood flowing out of the cannula was collected in cuvettes that allowed de termination of both O2 saturation of hemoglobin in an American Optical 10850 Micro-Oximeter and sample volume. (Such derivation of O2 content from hemoglobin spectrophotometry agrees with Van Slyke manometric determination within 1% (Fal holt, 1963) , a finding we have confirmed for the range of O2 saturation found in the present experi ments). Hemoglobin concentration, determined by the cyanmethemoglobin method (Sigma Kit No. 525) , along with O2 saturation, allowed calculation of O2 content. A value of CMR02 was obtained by multiplying SSBF by the difference in O2 content between aortic and sagittal sinus blood.
Samples of sagittal sinus blood were collected for 0.7-1 min at intervals of 3-10 min until successive flow values agreed to within 10%. Then ETC02 was increased to 8% by adding a metered amount of CO2 to the inspired gas, and was maintained at that level for 20 min. Arterial and sagittal sinus blood samples were obtained periodically during the hypercapnia. ETC02 was then returned to 4%. Next, about 1 h after completion of the hypercapnic period, an i.v. infusion of physostigmine sulfate (Merck, 2 mg/ml in 0.9% NaCl) was given at 0.04 mg kg-1 min-1 for 30 min, during which blood samples were taken at timed intervals.
Recording of ICBF
The external carotid artery and any extracranial branches of the internal carotid artery were ligated on the right side. A Biotronex electromagnetic cuff-type flow probe, 1-1.5 mm in diameter, was placed around the common carotid artery for mea surement of ICBF with a Biotronex 410-2 flowme ter. A hydraulic occluder (Debley, 1971) was placed distally to the flow probe. ICBF has previously been shown to be a good estimate of CBF in the rabbit (Schmidt and Hendrix, 1938; Scremin et aI., 1977 Scremin et aI., , 1982 .
To assess the responses of ICBF and mean arte rial pressure (MAP) to hypercapnia, ETC02 was varied in steps between 2 and 8% by hyperventila tion or addition of CO2 to the inspired gas. A period of 2-3 min was allowed after each step change in ETC02 to permit ICBF to reach a new stable level (Fig. 2) . Paired values of ETC02 and ICBF, and of ETC02 and MAP, were obtained in order to calcu late the regressions of ICBF and MAP on ETC02 by the least squares method. The slopes of these re gressions represent the changes in ICBF (percent of the control value) or in MAP (mm Hg) per unit change (volume percent) in ETC02• These are quantitive estimates of the cerebrovascular and the MAP responses to CO2 (C02 reactivities).
Carbon dioxide reactivities were determined at the beginning of the experiment. After at least 1 h, physostigmine sulfate (0.15 mg/kg, i. v.) was given and CO2 reactivities again determined. One hour later (15-45 min after ICBF and CO2 reactivities returned to control level), an infusion of dihydro beta-erythroidine hydrobromide (18 mg kg-1 h-t, i.v.) was started; 10 min later, physostigmine was again injected at the previous dose and CO2 reac tivities again determined. Following another 1-h interval, atropine sulfate (2.5 mg/kg, i.v.) was given, physostigmine again administered, and CO2 reac tivities reassessed. In a separate group of rabbits, the same procedure was followed to test the effect of neostigmine bromide (0.3 mg/kg, i.v.).
The physostigmine dose was selected on the basis of the threshold intravenous dose necessary for potentiation of bradycardia induced by vagal stimulation (0.10 mg/kg); physostigmine itself in duced no effect on heart rate of vagotomized animals below a dose of 1.0 mg/kg. The dose of dihydro beta-erythroidine used was selected on the basis of its ability to produce a nicotinic ganglionic blockade as evidenced by a decrease in arterial pressure from 98 ± 6 (SE) to 69 ± 6 mm Hg. The selected dose of atropine, while higher than that required for block ing of most peripheral cholinergic effects, is within the range necessary to inhibit central cholinergic receptors (Bradley and Elkes, 1957) . The dose of neostigmine selected is somewhat higher than that required to produce cholinesterase inhibition (Blasch ko et aI., 1949) .
Significances of the differences between mean CO2 reactivities or between the means of ICBF and MAP at ETC02 of 4% (normocapnia) were tested by analysis of variance with repeated measures (Winer, 1962) . The Dunnet's t statistic was used to compare means of variables in the different experi mental groups with control means (Dunnet, 1955) .
RESULTS

Effects of Hypercapnia and Physostigmine on SSBF and CMR02
In a group of six animals, before physostigmine administration, cerebrovascular responsiveness was tested with hypercapnia (ETC02 of 7.9 ± 0.2% (SE)), which induced an increase in SSBF that reached, within 2-5 min, a steady average level of 160 ± 6% of control, representing a CO2 reactivity (calculated as described in Methods) of 16 ± 2. The average CMR02 reached a level of 116 ± 9%, while MAP rose slightly from an initial 83 ± mm Hg to 87 ± mm Hg during hypercapnia (Fig. O. After the response to CO2 was tested and the animals were again normocapnic, physostigmine infusion was started. SSBF increased, reaching in 12 min a peak of 290 ± 34% of control, then falling were before infusion: SSBF = 0.54 ± 0.08, A -V = 87 ± 5, CMR02 = 48 ± 9; and at peak of effect during infusion (12 min): SSBF = 1.5 ± 0.27, A V = 29 ± 3, CMR02 = 44 ± 8. off to 154 ± 14% of control at 30 min. During the entire period, CMR02 remained slightly below the initial value. MAP showed a small increase during the first few minutes of the infusion and then re turned to control levels (Fig. 1) . above). Physostigmine induced an elevation of this CO2 reactivity to 31 ± 7 (Table 1; Figs. 2 and 3 ). Normocapnic flow also increased to 146 ± 18% of control. This phenomenon was unaffected by dihydro-beta-erythroidine (Table 1; Fig. 3 ). At ropine, however, prevented the cerebral vasodila tation and the enhancement of CO2 reactivity in duced by physostigmine (Table 1; Figs. 2 and 3) . The CO2 reactivity of MAP was small and no differ ences were found among the levels of MAP at normocapnia in the control, physostigmine, and physostigmine plus dihydro-beta-erythroidine groups. In the physostigmine plus atropine group,
Effects of Cholinergic Agents on ICBF and CO2 Reactivities
In a group of five animals, control CO2 reactivity of ICBF was 14.2 ± 3, comparing well with the reactivity observed with recording of SSBF (see Each plot shows the regression of ICBF on ETC02 for a group of five rabbits, calculated as described in text. The value of ICBF at ETC02 of 4% (normocapnia) is highlighted by the dot and broken line in each group. (See Table 1 for details.)
however, MAP was slightly lower than the control value (Table O. In a separate series of five animals, control CO2 reactivity of ICBF was 14 ± 2 and no significant change was observed after neostigmine (12 ± 2). Normocapnic flow, however, was significantly lower after neostigmine (81 ± 6% of control; p < 0.05) (Table 1) .
DISCUSSION
The existence of cholinergic cerebrovascular ef fects both in vitro (Edvinsson et aI., 1977) and in vivo (Scremin et aI., 1973; Kuschinsky et aI., 1974) is well documented, but the relevance of these re sponses to the physiological mechanisms that con trol CBF remains to be established. It has been suggested that cholinergic mechanisms may play a role in the autoregulatory dilatation of cerebral blood vessels secondary to hypotension (Mched lishvili and Nikolaishvili, 1970) , in the increase of CBF associated with cortical activation (Scremin et aI., 1973) , and in the cerebrovascular effects of hypercapnia (Rovere et aI., 1973; Scremin et aI., 1978) .
The evidence for these possible roles of choliner gic mechanisms is indirect and is based mainly on the effects of cholinomimetic or cholinolytic drugs on CBF. Particularly striking is the large increase in CBF observed following systemic (Rovere et aI., 1973; Scremin et aI., 1978) or local (Scremin et aI., 1973) administration of the cholinesterase inhibitor physostigmine. If this increased flow were accom panied by a proportional increase in cerebral meta-bolic rate, the phenomenon might be explained by the action of locally released "metabolites." The present investigation shows, however, that CMR02 actually does not change significantly at the time when CBF increases threefold during physostig mine administration. Moreover, the primarily vas cular nature of the cholinergic cerebral vasodilata tion was suggested earlier (Scremin et aI., 1973) by the observation that cholinomimetic drugs, top ically applied to the cerebral cortex, could still elicit vasodilatation when neuronal electrical activity had been abolished pharmacologically.
Despite the known effects of physostigmine and other cholinergic agonists on electrical and reflex neuronal activity (Schweitzer and Wright, 1938; Malcolm et aI., 1967; Yamamoto and Domino, 1967; Engelhardt and Decima, 1976) , such effects in our experiments evidently result in no increase in cere bral metabolism that can account for the large ob served change in CBF.
The large increase in blood flow observed fol lowing intravenous physostigmine administration is most likely related to the enhanced availability of acetylcholine induced by this agent and not to direct effects on cholinergic receptors. This follows, first, from the fact that physostigmine manifests only weak direct effects on cholinergic receptors and then at much higher doses than required to inhibit cholinesterase (Riker and Wescoe, 1946; Cullum bine, 1963) . Doses of physostigmine that elicited ce rebral vasodilatation in our experiments are close to the minimal doses required to potentiate vagal bradycardia, and considerably below that necessary to elicit bradycardia unrelated to vagal stimulation. Moreover, Eccles et al. (1954) have shown that doses of 0.2-0.5 mg/kg of physostigmine prolong the repetitive discharge of Renshaw cells, while spontaneous firing is induced only at doses of 1.0 mg/kg or higher.
An interesting characteristic of the cerebral vaso dilatation produced by physostigmine is the de crease observed after 12 min of continuous intrave nous infusion. A possible explanation is that the infusion may induce a steady rise in physostigmine concentration in the central nervous system that will eventually block transmission in a neurovascu lar synapse after the initial enhancement, as is known to occur in other cholinergic synapses (Taylor, 1980) . Alternatively, the lowered tissue CO2 induced by the initial hyperemia may play a role in this phenomenon, since the physostigmine action is CO2-dependent, as shown in previous ex periments (Rovere et aI., 1973; Scremin et aI., 1978) and in the present work (Fig. 3) .
The fact that atropine blocks the cerebrovascular effects of physostigmine, while the nicotinic blocker dihydro-beta-erythroidine fails to do this, confirms the muscarinic nature of the receptors involved in these effects. Since neostigmine is approximately equipotent with physostigmine in its known peripheral cholinergic actions (Blaschko et al. 1949) , the failure of neostigmine in our experiments to elicit cerebrovascular effects like those of physostigmine most likely results from the dem onstrated inability of quaternary cholinesterase inhibitors to cross the blood-brain barrier (Koelle and Steiner, 1956) . This suggests that the choliner gic cerebrovascular receptors are located beyond this barrier. Under many circumstances, cerebral vasodilata tion is closely correlated with metabolic activation. It has been suggested that this relationship depends on alteration in the perivascular milieu resulting from changes in cellular metabolism (Lassen, 1968 ). On the other hand, the physostigmine-induced vaso dilatation in the absence of cerebral metabolic ac tivation indicates that a cholinergic vasodilator mechanism may play a role in cerebrovascular reg ulation parallel to or independent of metabolic acti vation.
